Researchers screened 914 patients who were refractory to chemotherapy and had KRAS wild-type CRC, identifying 46 patients as having HER2-positive disease and enrolling 27 eligible patients into the study. This evidence concerns the gene ERBB2 and colorectal carcinoma.